In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on RedHill Biopharma (NASDAQ: RDHL), with a price target of $36. The company’s shares closed on Friday at $7.48.
Ramakanth noted:
“We are maintaining our Buy rating on RedHill and our 12- month price target of $36.00 per ADS based on the average of two valuation methods: (1) price-sales multiple using 7x 2025 sales estimate discounted at 14%; and (2) price-earnings multiple analysis applying a 15x multiple to our 2025 estimated earnings also discounted at 14%.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 11.9% and a 44.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RedHill Biopharma with a $28 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.49 and a one-year low of $4.30. Currently, RedHill Biopharma has an average volume of 263.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill’s pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs.
